Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01182077 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess Drug Interaction of ASP015K and Midazolam

A Phase 1 study, sponsored by Astellas Pharma.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target

NCT01182077: Completed Phase 1 study, sponsored by Astellas Pharma.

NCT01182077 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01182077, a Phase 1 study, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target

Study Summary

The objective of the study is to characterize the effect of multiple doses of ASP015K on the pharmacokinetics of a single dose of midazolam.

Interventions

  • DRUG Midazolam
  • DRUG ASP015K

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2010-06
Est. Completion 2010-07
Phase Phase 1
Astellas Pharma

165 total trials

What the finished NCT01182077 record still lists

NCT01182077 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).

The record links to 0 conditions, and to 2 interventions - of which Midazolam is the first listed.

NCT01182077 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01182077 about?

NCT01182077 is a clinical study titled "A Study to Assess Drug Interaction of ASP015K and Midazolam". The objective of the study is to characterize the effect of multiple doses of ASP015K on the pharmacokinetics of a single dose of midazolam.

What is the current status of trial NCT01182077?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2010-06. Estimated completion is 2010-07.

What interventions are being tested in trial NCT01182077?

The interventions under investigation include: Midazolam (DRUG), ASP015K (DRUG).

Who is sponsoring clinical trial NCT01182077?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01182077's enrollment target sits among peer trials

30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01182077, the US trial registry maintained by the National Library of Medicine. NCT01182077 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.